CA2252501A1 - Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors - Google Patents
Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors Download PDFInfo
- Publication number
- CA2252501A1 CA2252501A1 CA002252501A CA2252501A CA2252501A1 CA 2252501 A1 CA2252501 A1 CA 2252501A1 CA 002252501 A CA002252501 A CA 002252501A CA 2252501 A CA2252501 A CA 2252501A CA 2252501 A1 CA2252501 A1 CA 2252501A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- disease
- arylalkyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
A compound of general formula (i), wherein R is H, halogen or alkyl; R1 represents OH, alkoxy optionally substituted with one or more halogens, or thioalkyl; R2, R3 and R4 are the same or different and are each H, R7, OR11, COR7, C(=NOR7)R7, alkyl-C(=NOR7)R7, alkyl-C(=NOH)R7, C(=NOH)R7, halogen, CF3, CN, CO2H, CO2R11, CONH2, CONHR7, CON(R7)2, NR9R10 or CONR12R13 where NR12R13 is a heterocyclic ring optionally substituted with one or more R15; R5 represents H, arylalkyl, heteroarylalkyl, S(O)mR11 or alkyl optionally substituted with one or more substituents chosen from hydroxy, alkoxy, CO2R8, SO2NR12R13, CONR12R13, CN, carbonyl oxygen, NR9R10, COR11 and S(O)nR11; R6 represents aryl, heteroaryl, arylalkyl or heteroarylalkyl. The compounds can be used to treat disease states, for example disease states associated with proteins that mediate cellular activity, for example by inhibiting tumour necrosis factor and/or by inhibiting phosphodiesterase IV.
Description
CA 0225250l l998-l0-20 QUrNOLlNE SULFONAMIDES AS TNF ~H~ VRS AND AS PDE~ nll)l ll~RS
Field of the Invention The present invention relates to novel qllinolinps~ and to their forrnu~tion and use as phar n~rp~tir~lc S Bac3c~round of the Invention ~~ J~rp~nf se Patent Publi~tiorl 2- 184673 dicclQses qninolines~lphon~.lides.US-A-4910193 dicrloses q~inolin~s~lphon~ in which the s~ hon~ ide nitrogen is s~bstitut~d by a variety of bridged saturated ring systems, as ..,e~ "~
suitable for the lreaL..lcnt of serotonin-induced g~SIlO;~If CI;.~li distl IbanCeS.
US-A4857301 and US-A-5340811 disrlose ~ nc.linesull~hon~.~;d~ in the ,~t.l,~nL of asthrna, l~ ,e~ rely as bronr-ho~ tors and as anti-allergic compol~n~
Phospho~liPcterases (PDE) and Tumour Necrosis Factor (TNF), their modes of action and the therapeutic utilities of inhibitors thereof, are described in WO-A-9636595, WO-A-9636596 and WO-A-9636611, the coll~rnl~; of which are inco.~.o,~Led herein by 15 r~.ence. The same doc~erlts dicclose sulphon~nid~c having utility as PDE and TNF
i~h~ r~.
Summarv of the Invention This invention is based on the discovery of novel compounds that can be used to treat disease states, for example disease states ~Ccori~t~d with proteins that mediate 20 cellular activity, for ~mple by inhibiting tumour necrosis factor and/or by in~il,il;np.
phosphodiest~rase IV. According to the invention, the novel compounds are of forrnula (i):
N~R3 l l R1 ~ ~ R4 RJ~SO~- N ~R5 (i) 6 wherein R is H, halogen or alkyl;
I
CA 022~2~0l l998-l0-20 Rl represents OH, alkoxy optionally substituted with one or more halogens, or thioalkyl;
R2, R3 and R4 are the same or different and are each H, R7, ORIl, COR7, C(=NOR7)R7, alkyl-C(=NOR,)R7, alkyl-C(=NOH)R7, C(=NOH)R7, halogen, CF3, CN, CO2H, CO2RIl, CONH2, CONHR7, CON(R7)2, NRgRIo or CONRI2Rl3 where NRI2Rl3 is a heterocyclic ring (such as morpholine or piperidine) optionally substituted with one or more Rl5;
Rs ~,p.cs~nt~ H, arylalkyl, heteroarylalkyl, S(O)mRII or alkyl optionally s~bstit~tted with one or more substit~ents chosen from hydroxy, alkoxy, CO2Rg, SO,NRI2Rl3, 10 CONRI2R,3, CN, carbonyl oxygen, NR9R~o, CORII and S(O)nRII;
R6 ~e~)resenLs aryl, heteroaryl, arylalkyl or heteroarylalkyl;
in R5 and/or R6, the aryllheteroaryl portion is optionally substituted with one or more substitllents alkyl-RI4 or Rl4;
R7 represe"ls Rll optionally substituted at any position with (one or more) R,6;lS R8 represents H, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R9 represents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkyl~ alkylcarbonyl, alkoxycarbonyl, arylsulphonyl,heteroarylsulphonyl, heterocyclosulphonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl or alkylsulphonyl;
R~o rep~ esents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
Rl I I ep, ~se~ls alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, hete(tJ~ylalkyl or heterocycloalkyl;
R,2 and Rl3 are the same or different and are each H or Rll, or NRI2Rl3 ~eplese.lts 25 a heterocyclic ring as defined above;
Rl4 rc~, esellLs alkyl (optionally substituted by one or more h~log~nc), cycloalkyl, aryl, heteroaryl, heterocyclo, hydroxy, alkoxy (optionally substituted by one or more halogens), thioalkyl, aryloxy, heteroaryloxy, heterocyclooxy, arylalkyloxy, heteroarylalkyloxy, heterocycloalkyloxy, CO2R8, CONRI2Rl3, SO2NRI2Rl3, halogen, -CN, 30 -NRgRIo~ CORIl, S(O)nR", or (where appropriate) carbonyl oxygen;
R,5 represents alkyl, arylalkyl or heteroarylalkyl;
CA 022~2~0l l998-l0-20 R,6 r~ .,sents alkyl, OH, OR", NI~Rlo, CN, CO2H, CO2R,I, CONR,2RI3 or CORI,;
m .ep-~se,-Ls 1-2; and n represe.,l~ 0-2;
5 and pharm~centir~lly-acceptable salts.
Co-.~binalions of substituents and/or variables are only permissible if such cc.".l~,n~;ons result in stable compounds.
Description of the Invention Suitable pharmaceutically-acceptable salts are pharm~eutic~lly-acceptable base 10 salts and pharm~eutir~lty-acceptable acid addition salts. Certain of the compounds of formula (i) which contain an acidic group form base salts. Suitable pharrn~ce~ltic~lly-acceptable base salts include metal salts, such as alkali metal salts for example sodium salts, or organic amine salts such as that provided with ethylene(li~rnime.
Certain of the compounds of formula (i) which contain an amino group form acid 15 addition salts. Suitable acid addition salts include pharm~r,entiç~ily-acceptable inorganic salts such as the ~Jlph~tP., nitrate, ph~s~,h~l~, borate, hydrochloride and hydrobromide and pharm~r,e~ltir~lly-~cce~ ble organic acid addition salts such as acetate, tartrate, maleate, citrate, succin~tç, bPn~o~te, ascorbate, meth~nPslllphate, a-ketoglutarate, a-glycerophosrh~te and glucose- I -phosph~te The pharmaceutically-acceptable salts of the 20 compounds of formula (i) are prepared using conventional procedures.
It will be appre~,;ated by those skilled in the art that some of the compounds of formula (i) may exist in more than one tautomeric form. This invention extends to all t llltomeric forms.
It will be app.~ciated that the compounds according to the invention can contain25 one or more asymmetrically substituted atoms. The presence of one or more of these asymmetric centers in a compound of formula (i) can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, inrlu~ing enantiomers, and diastereoisomers and mixtures including racemic mixtures thereof.
When used herein the term alkyl whether used alone or when used as a part of 30 another group includes straight and branched chain alkyl groups containing up to 6 atoms.
Alkoxy means an alkyl-O- group in which the alkyl group is as previously desc,;bed.
Aryloxy means an aryl-O- group iA which the aryl group is as defined below.
CA 022=,2=,01 1998-10-20 ~eteroà~yloxy means a heteroaryl-O- group and heterocyclooxy means a heterocyclo-O-group in which the heteroaryl and heterocyclo group are as defined below. Alkylamino means an alkyl-N- group in which the alkyl group is as previously defined, arylamino means aryi-N- and heteroarylamino means an heteroaryl-N- group (aryl and heteroaryl 5 defined below). Thioalkyl means an alkyl-S-group. Cycloalkyl includes a non-aro".alic cyclic or multicyclic ring system of about 3 to 10 carbon atoms. The cyclic alkyl may optionally be partially unsaturated. Aryl ilUlic~tes carbocyclic radicals co~ ;,.;.,g about 6 to 10 carbon atoms. Arylalkyl means an aryl-alkyl- group wherein the aryl and alkyl are as des~,(;l,cd herein. Heteroarylalkyl means a heteroaryl-alkyl group and heterocycloalkyl 10 means a heterocyclo-alkyl group. Alkylcarbonyl means an alkyl-CO- group in which the alkyl group is as previously described. Arylcarbonyl means an aryl-CO- group in which the aryl group is as previously described. Heteroarylcarbonyl means a heteroaryl-CO-group and heterocyclocarbonyl means a heterocyclo-CO- group. Arylsulphonyl means an aryl-SO2- group in which the aryl group is as previously described. Heteroarylsulphonyl 15 means a heteroaryl-SO2- group and heterocyclosulphonyl means a heterocyclo-SO2-group. Alkoxycarbonyl means an alkyloxy-CO- group in wich the alkoxy group is aspreviously desribed. Alkylsulphonyl means an alkyl-SO2- group in which the alkyl group is as previously described. Carbonyl oxygen means a-CO- group. It will be apprec;ated that a carbonyl oxygen can not be a substituent on an aryl or heteroaryl ring. Carbocyclic 20 ring means about a 5 to about a 10 membered monocyclic or multicyclic ring system which may saturated or partially unsaturated. Heterocyclo ring means about a 5 to about a 10 memb.~red monocyclic or multicyclic ring system (which may saturated or partially unsaturated) wherein one or more of the atoms in the ring system is an element, other than carbon chosen from amongst nitrogen, oxygen or sulphur atoms. Examples include 25 morpholine and piperidine. Heteroaryl means about a 5 to about a 10 membered aromatic monocyclic or multicyclic hydrocarbon ring system in which one or more of the atoms in the ring system is an element other than carbon, chosen from amongst nitrogen, oxygen or sulphur; if desired, a N atom may be in the form of an N-oxide. Heterocyclo means about a 5 to about a 10 membered saturated or partially saturated monocyclic or 30 multicyclic hydrocarbon ring system in which one or more of the atoms in the ring system -CA 022~2~01 1998-10-20 is an element other than carbon, chosen from amongst nitrogen, oxygen or sulphur.
Halogen means fluorine, chlorine, bromine or iodine.
Compo~n~s ofthe invention are useful for the treatment of TNF mediated disease states. HTNF m~i~ted disease or disease states'' means any and all disease states in which 5 TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL- I or IL-6. A disease state in which ~-1, for inct~nrP., is a major comrone--t, and whose productior or action is exacerbated or secreted in response to TNF, would therefore be considered a disease state me(li~ted by TNF. As TNF-,~ (also known as Iymphotoxin) has close structural homology ~,vith TNF-~ (also 10 known as cachectin), and since each induces similar biologic responses and binds to the same cellular .~,ceptor, both TNF-a and TNF-~ are concidçred to be inhibited by comroun~lC of the present invention and thus are herein I ef~"ed to collectively as "TNF"
unless specific~lly indicated otherwise.
This invention relates to a method for me~i~tin~ or ;~ b:~;n~ the enzymatic activity 15 or catalytic activity of PDE IV in a mammal in need thereof and for inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said marnrnal an effective amount of a compound of Formula (i) or a pharm~ceutic~JIy-acceptable salt thereof.
PDE IV inhibitors are useful in the lle~ llfl~t of a variety of allergic and 20 ;.,n~..",.~,O,y diCP~C,P$, in~ rling asthma, chronic bronchitis, chronic obstructive airways disease, atopic d~ is~ atopic eC7~n~ urticaria, allergic rhinitis, allergic conjunctivitis, vernal co~ nctivitis~ infl~mm~tion of the eye, allergic responses in the eye, eosinophilic gr~nlllom~, psoriasis, Bechet's disease, erythem~tocis anaphylactoid purpura nephritis, joint ir,n~",...~tion, arthritis, rheumatoid arthritis and other arthritic conditions such as 2S rhe~lm~toii spondylitis and osteoarthritis, septic shock, sepsis, ulcerative colitis, Crohn's dice~ce, reperfilsion injury of the myocardium and brain, chronic glomerulonep~;lis, endotoxic shock and adult respiratory distress syndrome. In addition, PDE IV inhibitors are useful in the treatmPnt of diabetes insipidus and conditions associated with cerebral metabolic inhibition, such as cerebral senility, senile dementia (Alzheimer's disease), 30 memory impairment associated with Parkinson's disease, depression and multi-infarct dementia. PDE IV inhibitors are also useful in conditions ameliorated by neuroprotectant activity, such as cardiac arrest, stroke and intermittent claudication. PDE IV inhibitors CA 022~2~01 1998-10-20 may be useful in the treatment of tardive dys~inPsi~ i.cch~emi~ and Huntingdon's disease.
Additionally, PDE IV inhibitors could have utility as gastroprotect~ntc A special embodiment of the therapeutic methods of the present invention is the treatmene of asthrna.
S The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replic?tion, directly or indirectly, by the TNF inhibitors of Formula (i). Such viruses incl~lds, but are not limited to HIV-I, HIV-2 and ~V-3, cytomegalovirus ~CMV), inflllen7~ adenovirus and the Herpes group of viruses, such as, but not limited to, ~erpes zoster and Herpes simplex.
This invention more specifically relates to a method of t~ eali,~g a m~mm~l afflicted with a human immunodeficiency virus (HIV), which comprises administering to suchrn~mm~l an effective TNF inhibiting amount of a compound of Formula (i) or a pharm~ce~ltic~lly-acceptable salt thereof.
The compounds of this invention may also be used in association with the veterinary tre?tm.ont of ~nim~lc other than humans, in need of inhibition of TNFproducSion TNF mediated ~i~e~CPs for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections.
Examples of such viruses include, but are not limited to feline immunodeficiency virus (E~IV) or other retroviral infection such as equine infectious anae.,lia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses.
The compounds of this invention are also useful in tr~,aLing parasite, yeast andfungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo. A pl~rel~d disease state for l~ lllcnt is fungal l"f.ni~ ;c Compounds of the invention may also suppress neurogenic infl~mm~sion through elevation of cA~ in sensory neurones. They aret therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory ~lice~ses associated with irritation and pain.The compounds of forrnula (i) are preferably in pharm~ceutically-acceptable form.
By pha~ c~utic~lly-acceptable form is meant, rnt~r alia, of a pharmaceutically-acceptable level of purity r~clllding normal phalm~ceutir~l additives such as diluents and carriers, and incl~l~in~ no material considered toxic at normal dosage levels. A pharn~ce~ltic~lly-CA 022~2~01 1998-10-20 acce~i '' level of purity will generally be at least 50% PXcluding norrnal pharmaceuti additives, preferably 7S%, more preferably 90% and still more preferably 95%.
The invention filrther provides a process for the preparation of a compound of formula (i), in which Rl etc, m and n are as defined above. It will be appreciated that S functional groups such as amino, hydroxyl or carboxyl groups present in the various compounds d~lil.ed below, and which it is desired to retain, may need to be in protected forms before any reaction is initiated. In such instances, removal of the protecting group may be the final step in a particular reaction sPqu~nce Suitable protecting groups for such filn~ion~lity will be appalenL to those skilled in the art. For specific details, see Protective 10 Groups in Organic Synthesis, Wiley Interscience, TW Greene. Thus the process for p.~,pali"g compounds of formula (i) in which R3 contains an -OH col"~,lises of deprotecting (for example by hydrogenolysis or hydrolysis) a compound of formula (i) in which R3 contains an appropriate -OP wherein P ~epr~se.l~s a suitable protecting group (e.g. benzyl or acetate).
lS It will be appreciated that where a particular stereoisomer of forrnula (i) is required, this may be obtained by conventional resolution techniques such as high performance liquid chromatography or the synthetic processes herein described may by perforrned using the appropriate homochiral starting material.
A process for the ~l~p~tion of a compound of forrnula (i) comprises reaction of 20 an appropriate sulphonyl chloride of forrnula (ii) with a suitable amine of formula (iii) R2a R2a ~ R3a N~ R3a R~,~ R HNRSaR6a R1~ R4a R so2a R S02NR5aR6a (ii) (ia) wherein R" I ~),esenLs R~ as defined in relation to formula (i) or a group convertible to R~
and R2,-R6, similarly represent R2-R~ or groups convertible to R2-R6 respectively; and thc.eafler, if required, converting any group R" to Rl and/or R2, to R, and/or R3, to R3 and/or R" to Rl and/or Rs~ to R5 and/or converting any group R~5, to R6. The reaction of a sulphonyl chloride of forrnula (ii) with an amine of formula (iii) may be carried out under any suitable c~ itionc known to those skilled in the art. Preferably, the reaction is carried 5 out in the presence of a suitable base, for example an amine such as triethylamine, preferably in an app-op-iate solvent such as dichlorome~h~ne In some cases a sl-or.g~,r base, such as sodium hydride, and a polar solvent such as dimethylro...,~.";de, will be required.
Sulphonyl chlorides of formula (ii) are either commercially available, previously 10 de~lil,ed compounds or are prepared using standard procedures known to those skilled in the art. For e,,- , 'e, a sulphonyl chloride of formula (ii) is conveniently prepared from the approp-ia~e sulphonic acid (iv) N~ R3a R1 a~ R4a R ~ S03H
(iv) by ll~l .J~..-L with a suitable agent such as thionyl chloride or oxalyl chloride. Alternatively, a sulphonyl chloride of formula (ii) may be prepared by sulphonylation of an app~ op. ia~e qllinoline of formula (v) N~ R3a R1 a~ ~ R4a R~
(v) 30 with a suitable sulphonylating agent such as chlorosulphonic acid.
Compounds offormula (v) are either co,.uue.c;ally-available, previously described compounds or are p..,pared using standard procedures known to those skilled in the art., CA 022~2~01 1998-10-20 For ~ r 1~ q~ oli~5 offormula (v) may be conveniently prepared by a Skraup reaction (Z.H. Skraup, Ber. 13:2086 (1880)).
A compound of formula (ia) may also be p.epared by reaction of a sulphonyl chloride offormula (ii) ~,vith an amine ofthe formula H2NR6, (vi), to provide a compound 5 of formula (ia) in which R5, is H, followed by reaction with an approp,iate agent of forrnula R5,Y (vii), wherein RI,-R6, are as defined above and Y represents a suitable leaning group such as halogen. The reaction of a sulphonyl chloride of formula (ii) with an amine of forrnula (vi) may be carried out under any suitable conditions known to those skilled in the art. P~ bly, the reaction is.carried out in the p.csel~ce of a suitable base, 10 for ~ pl& an arnine such as triethylamine, preferably in an approp~;ate solvent such as dichlo-o,~ e In some cases, a stronger base such as sodium hydride, and a polar solvent such as dimethylformamide, may be required.
The reaction of a compound of forrnula (ia) in which Rs~ is H with an agent of formula (vii) may be carried out under any suitable conditions known to those skilled in 15 the art. Preferably, the reaction is carried out using an appropriate base, such as sodium hydride, prere~bly in an appropriate solvent such as dimethylfor~mide Agents of forrnula (vii) are either conllne..;ially available or are prepared using standard procedures known to those skilled in the art. Agent (vii) can be an alkylating agent such as propyl bromide, an acylating agent such as benzoyl chloride or a sulphonylating agent such as 20 meth~nesnlphonyl chloride.
Amines of formulae (iii) and (vi) are commercially available, previously described cotnroun-ls or are prepared using standard procedures known to those skilled in the art.
A compound of forrnula (i) may also be prepa~cd by interconversion of other compounds of forrnula (i). For example, a compound in which R3 co..l~ins an alkoxy 25 group may be p.~,pared by appropriate alkylation of a compound in which R3 con~ C a hydroxy group.
Compounds in which R2-R4 contain a C0-alkyl, C0-aryl, CO-heteroaryl, CO-alkylaryl, CO-alkylheteroaryl or C0-alkylheterocyclo group may be prepared from compounds in which R2-R4 contain a CN group, by addition of a suitable organometallic 30 agent (such as a Grignard reagent).
By way of further example, compounds in which R2-R4 contain an oxime may be ,c.~;p~t;d from compounds in which R2-R4 contain a carbonyl group. This transformation . I
CA 022~2~01 1998-10-20 may be carried out using any a~ o~l iate ~ d~ ~I conditions known to those skilled in the art. Compounds of formula (i) in which R2-R, contain a carbonyl group may be reduced using standard conditions known to those skilled in the art (for example with sodium borohydride in an ap~.ul";ate solvent) to provide compounds in which R2-R4 conLail~s an 5 alcohol group. Comrounds in which R2-R4 is alkyl may be prepal~d by reduction of compounds in which R2-R4 is CO-alkyl using standard conditions known to those skilled in the art (for ~ .ple hydrazine hydrate in the presel-ce of a suitable base in an ap~,.."~.iale solvent). Other llol~.rOl lllations may be carried out on compounds of formula (i) in which R2-R, colltains a carbonyl group. Such tran~rul~llalions include, but are not 10 limited to, reductive amination and alkylation. Any ofthe above lldl1~rol.alions may be carried out either at the end of the synthesis or on an appropriate intermediate.
A compound of forrnula (i) or where appropriate a pharrn~ceutiç~lly-acceptable salt thereof and/or a pl-d~ e~ ~tic~lly-acce~,i ' le solvate thereof, may be administered per se or, preferably, as a pharm~Geutic~l composition also comprising a pharm~cPlltir~lly-~ccept~hle camier.
Accordingly, the present invention provides a pharm~ceutical composition COl~ lg a compound of formula (i) or where appropl idle a pharrnaceutically-accept~le salt thereof and/or a pharm~r,~otic~lly-acceptable solvate thereof, and a pharm~ceutic-~lly-acceptable carrier.
The active compound may be formul~ted for administration by any suitable route, the plef~led route depending upon the disorder for which tre~tm~nt is required, and is Inere~ably in unit dosage form or in a forrn that a human patient may arlminicter to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, p~ tel~l a~minic~ration or through the respiratory tract. Preparations may be designed to give slow release of the active ingredient.
The term pal~-~llelol as used herein includes subcutaneous injections, intravenous, intr~m..cc.ll~r, illLl~ al injection or infusion tecniques. In addition to the ~rea~ll. n~ of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc, the compounds of the invention are effective in the tre~tm~nt of humans.
The compositions of the invention may be in the form of tablets, c~rsules, sachets, vials, powders, granules, lozenges, suppositories, reconstit..t~l~le powders, or liquid CA 022~2~01 1998-10-20 preparations such as oral or sterile parenteral solutions or suspensions. Topical forrnl~l ttionC are also envisaged where appropriate.
~n order to obtain consistency of administration it is p. efe" ed that a composition of the invention is in the form of a unit dose.
SUnit dose p.es~t~;on forms for oral administration may be tablets and capsules and may contain conve..tional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tr~e~r~ntll, or polyvinylpyrrolidone; fillers for example microcrystalline celllllose, lactose, sugar, maize-starch, calcium phosph~t~" sorbitol or glycine; tabletting lubricants, for eY~mple m~gnesillm stearate; dic;nte~.~nts, for example starch, 10 polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically-acceptable wetting agents such as sodium lauryl sulphate.
The solid oral co~.,pos;lionC may be pl~o~ucd by conventional methods of blending, filling, t~l letting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.
15Such opcl~Lions are of course conventional in the art. The tablets may be coated acc~,di,-g to methot~c well known in normal pharmaceutical practice, in particular with an enteric coating.
Oral liquid preparations may be in the form of, for example, emulsions, syrups or elixirs, or may be presented as a dry product for l.cons~ tion with water or other suitable 20 vehicle before use. Such liquid pr~,~)al ations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl ce~ lQsç~ gelatin, hydroxyethylce~ ose, carboxymethylce~ lose~ aluminium stearate gel, hydrogenatededible fats; emulsi~ing agents, for example lecithin, sorbitan monooleate, or acacia, non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated 25 coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol;
preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
-Compositions may also suitably be presented for administration to the r~sp;latoly tract as a snuff or an aerosol or solution for a nebuliser, or as a microfine powder for 30 in~ tion, alone or in combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have di~meters of less than 50 ~lm, such as ~om 0.1 to 50 ~lm, pr~l~lably less than 10 ~lm, for ~ r!e from I to 10 ~lm, 1 to 5 ~lm or from CA 0225250l l998-l0-20 2 to 5 ~lm. Where at)plo~,idte, small amounts of other ant~ ullal;cs and bronchodilators for example sympatho~ .,c~ic amines such as isoprenaline, isoelharine~ c~lbut~mol~
phenyle~ e and ephedrine; corticosteroids such as predl isolone and adrenal stim~ ntc such as ACl~I may be jnrluded For parenteral ~lll;n;~l~aLion~ fluid unit dosage forrns are prepared utili7in~ the GO..~l-ulm~ and a sterile vehicle, and, depPn-~in~ on the cGnc~ ~nalion used, can be either suspçn~led or dissolved in the vehicle. In prcp&ling sol~tionc the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ~mpolule and sealing.
AdV~ adjuvants such as local Z~llAP,Il.. I;r" a preservative and buffering agents can be dissolved in the vehicle. To enh~nce the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral s~CppnciQrlc are pn l~arl_d in snbst~nti~lly the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation caMot be a,r,r~ 4 by filtration. The compound can be sterilised by exposure to ethylene oxide before suspe ,~ g in the sterile vehicle. Advant~eo~sly, a surfactant or wetting agent is in~lllded in the composition to facilit~te uniform distribution ofthe compound.
The co-npo~;liol-s may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of ~.";~ l . a~ion.
Compounds of formula (i), or if app,.,p. iat~ a pharm~ceutir~lly-acceptable saltthereof and/or a ph~ ~utir~lly ~c~rtable solvate thereof, may also be ~minictered as a topical form.~lqtion in co...hin~;on with convention~l topical c,, , :-ntc Topical for~ tionc may be presented as, for il~cl~nce~ O,..n~ s, creams or lotions, i~"pregnàled d-ess;ngs, gels, gel sticks, spray and aerosols, and may contain 25 appropriate conventional additives such as preservatives, solvents to assist drug penetration and ~molli~ntc in oi~ lcn1s and creams. The formulations may containcompatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
Suitable cream, lotion, gel, stick, oinll"e"l, spray or aerosol formulations that may 30 be used for compounds offormula (i) or if approp,iate a ph&,...~ceutically-acceptable salt thereof, are conventional fonnulations well known in the art, for ~ ple, as described in WO 97/44322 ~CT/GB97/01360 standard text books such as Harry's Cosmeticology published by Leonard Hill Boolcs, Rf- n~ on~:i P}~ hr,~ ~tirql Sciencec and the British and US Pharrnacopoeias.
Suitably, the compound of formula (i), or if approp~iate a pharm~ee~lticqlly-ae,c ','p~ e salt thereof, will co~ .;se ~om about 0.5 to 20% by weight of the formulqtion 5 favourably from about 1 to 10%, for example 2 to 5%.
The dose ofthe compound used in the ~re~l...e..~ ofthe invention will vary in the usual way with the se~ cneCc of the d;so~ , the weight of the sufferer, and the relative efficacy ofthe compound. However, as a general guide suitable unit doses may be 0.1 to lOOOmg, such a~s 0.5 to 200, 0.5 to 100 or 0.5 to lOmg, for example 0.5, 1, 2, 3, 4 or 5mg;
10 and such unit doses may be a~ lered more than once a day, for ~a"~?le 2, 3, 4, 5 or 6 times a day, but p,~ bly I or 2 times per day, so that the total daily dosage for a 70kg adult is in the range of about 0.1 to lOOOmg, that is in the range of about 0.001 to 20 mg/kg/day, such as 0.007 to 3, 0.007 to 1.4, 0.007 to 0.14 or 0.01 to 0.5mg/kg/day, for example 0.01, 0.02, 0.04, 0.05, 0.06, 0.08, O.1 or 0.2 mg/kg/day, and such therapy may 15 extend for a number of weeks or months.
When used herein the term "pharm-qGenticq-lly-acce~Jtable" cnco...pacses materials suitable for both human and v.,tel ;nal ~ use.
The following FY~ rloS illustrate the invention.
Intermediate 1 - 8-Methoxyqri-~el ~S-(N-benzyl)sulpl~or~ ide Triethylamine (0.38ml) was carefully added to a su~pens;on of 8-methoxyq~lino~;r~5-sulphonyl chloride (203mg) in dichloro...~ qnr, (lOml) at 0~C under nitrogen. Benzylarnine (90 ~l~ was then added and the mixture stirred for 30 minutes at 0~C and 16 hours at room te~ .e~a~ure~ The r~ ~otion was diluted with dichloro....,th~n~
(30ml), washed with water (15ml) and saturated aqueous sodium chloride (20ml). The 25 organic layer was dried over mq~gne~ium. sl~iphste~ filtered and the filtrate evaporated in ua~uo. The residue was purified by column chro...qtography on silica gel eluting with 2%
methqnol in dichlolo ~ ne to yield the titled compound as a white solid (135mg).Mp 150-151~C
E~amDle 1 8-Methoxyquinoline-S-(N-benzyl-N-methanes~lphoDyl)s~lpl~onamide Sodium hydride (120mg, 60% dispersion in oil) was added to a solution of 8-methoxyq~inol ne-5-(N-benzyl)sulphon~rnide (120mg) in anhydrous DMF (3ml) at 0~Cunder nitrogen. The resultant mixture was stirred for 20 minu~es and then treated with meth~nesulphonyl chloride (34~1). The reaction was stirred for one hour at 0~C and 18 hours at room te.llpe~ re. Water ( I ml) was carefiully added and the solvent evapol dted in vacuo. The residue was partitioned between dichlor~ nr (20ml) and saturated aqueous sodium hydrogen ca~bOnate solution (lOml). The aqueous layer was extracted 5 with dichloro..~e~ ne (lOml). The organic extracts were colllbined and washed with saturated ~lueo~ sodium chloride (lOml), dried over m~nPsillm sulphate, filtered and the filtrate e~,apol ~Led fn uacuo. The residue was purified by column cl~olllàtography on silica gel eluting with 10% ethyl acetate in dichloro...~ e to yield the title compound as a white solid (99mg) after trituration with diethyl ether.
10 TLC Rf 0.45 (5% ~(~.annl in dichlorcell.~ne) Mp 157-158~C
E~ample 2 8-Metho~yquinoline-S-(N-benzyl-N-propyl)sulphc Arni~
The title compound was obtained as a colourless gum (250mg) from 8-methoxyquinoline-5-(N-benzyl)sulphond.lude and blulnoplopane using a similar procedure to that described in Example 1.
TLC Rf 0.1 (50% ethyl acetate in hexane).
Assay methods The assays used to confirm the phosphodiesterase IV inhibitory activity of compounds of formula (i) are standard assay procedures as disclosed by Schilling et al, Anal. Biochem. 216:154 (1994), Thompson and Strada, Adv. Cycl. Nucl. Res. 8:119 (1979) and Gristwood and Owen, Br. J. Pharmacol. 87:91P (1986).
Compounds of formula (i) have P~hiL ;led activity at levels conci~t~nt with those believed to be useful in treating phosphodie~le,~se IV-related disease states in those assays.
The ability of compounds of formula (i) to inhibit TNF production in human peripheral blood monor-ucle~r cells (P~fBC's) is measured as follows. PMBC's are~ cp~ed from freshly taken blood or "Buf~ coats" by ~landaid procedures. Cells are plated out in RPMI1640 +1% foetal calf serum in the l)resence and -~s~ ce of ;n~.ib;~
LPS (100 ng/ml) is added and cultures are inc~lb~ted for 22 h at 3~~C in an atmnsrh~re 30 of 95% air/5% CO2. SupelaLants are tested for TNFa by ELISA using cGllulle~c;ally available kits.
In vivo activity in a skin eosinophilia model is deterrnined by using the methods des~.;l,ed by Hellewell et al, Br. J. Pharmacol. 111 :811 (1994) and Br. J. Ph&,...acol.
110:416 (1993). Activity in a lung model is measured using the procedures desc~ibed by Kallos and Kallos, Lnt. Archs. Allergy Appl. Tmmllnol. 73 :77 (1984), and Sanjar et al, Br.
5 J.PI.~ 1 99:679(1990).
An additional lung model, which allows measurement of inhibition of the early and late-phase ~clh n~;c re,l,o~ s and also the inh;hition of airway h~,e..eacli~ity, is dcs~,;bed by Broadley et al, Pulmonary Pharmacol. 7:311 (1994), J. Tmml~ og Methods 190:51 (1996) and British J. Pharrnacol. 116:2351 (1995).
10 Abbreviations LPS Lipopolysaccharide (endotoxin) ELISA Enzyme linked imm~nosorbent assay ,,,
Field of the Invention The present invention relates to novel qllinolinps~ and to their forrnu~tion and use as phar n~rp~tir~lc S Bac3c~round of the Invention ~~ J~rp~nf se Patent Publi~tiorl 2- 184673 dicclQses qninolines~lphon~.lides.US-A-4910193 dicrloses q~inolin~s~lphon~ in which the s~ hon~ ide nitrogen is s~bstitut~d by a variety of bridged saturated ring systems, as ..,e~ "~
suitable for the lreaL..lcnt of serotonin-induced g~SIlO;~If CI;.~li distl IbanCeS.
US-A4857301 and US-A-5340811 disrlose ~ nc.linesull~hon~.~;d~ in the ,~t.l,~nL of asthrna, l~ ,e~ rely as bronr-ho~ tors and as anti-allergic compol~n~
Phospho~liPcterases (PDE) and Tumour Necrosis Factor (TNF), their modes of action and the therapeutic utilities of inhibitors thereof, are described in WO-A-9636595, WO-A-9636596 and WO-A-9636611, the coll~rnl~; of which are inco.~.o,~Led herein by 15 r~.ence. The same doc~erlts dicclose sulphon~nid~c having utility as PDE and TNF
i~h~ r~.
Summarv of the Invention This invention is based on the discovery of novel compounds that can be used to treat disease states, for example disease states ~Ccori~t~d with proteins that mediate 20 cellular activity, for ~mple by inhibiting tumour necrosis factor and/or by in~il,il;np.
phosphodiest~rase IV. According to the invention, the novel compounds are of forrnula (i):
N~R3 l l R1 ~ ~ R4 RJ~SO~- N ~R5 (i) 6 wherein R is H, halogen or alkyl;
I
CA 022~2~0l l998-l0-20 Rl represents OH, alkoxy optionally substituted with one or more halogens, or thioalkyl;
R2, R3 and R4 are the same or different and are each H, R7, ORIl, COR7, C(=NOR7)R7, alkyl-C(=NOR,)R7, alkyl-C(=NOH)R7, C(=NOH)R7, halogen, CF3, CN, CO2H, CO2RIl, CONH2, CONHR7, CON(R7)2, NRgRIo or CONRI2Rl3 where NRI2Rl3 is a heterocyclic ring (such as morpholine or piperidine) optionally substituted with one or more Rl5;
Rs ~,p.cs~nt~ H, arylalkyl, heteroarylalkyl, S(O)mRII or alkyl optionally s~bstit~tted with one or more substit~ents chosen from hydroxy, alkoxy, CO2Rg, SO,NRI2Rl3, 10 CONRI2R,3, CN, carbonyl oxygen, NR9R~o, CORII and S(O)nRII;
R6 ~e~)resenLs aryl, heteroaryl, arylalkyl or heteroarylalkyl;
in R5 and/or R6, the aryllheteroaryl portion is optionally substituted with one or more substitllents alkyl-RI4 or Rl4;
R7 represe"ls Rll optionally substituted at any position with (one or more) R,6;lS R8 represents H, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R9 represents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkyl~ alkylcarbonyl, alkoxycarbonyl, arylsulphonyl,heteroarylsulphonyl, heterocyclosulphonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl or alkylsulphonyl;
R~o rep~ esents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
Rl I I ep, ~se~ls alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, hete(tJ~ylalkyl or heterocycloalkyl;
R,2 and Rl3 are the same or different and are each H or Rll, or NRI2Rl3 ~eplese.lts 25 a heterocyclic ring as defined above;
Rl4 rc~, esellLs alkyl (optionally substituted by one or more h~log~nc), cycloalkyl, aryl, heteroaryl, heterocyclo, hydroxy, alkoxy (optionally substituted by one or more halogens), thioalkyl, aryloxy, heteroaryloxy, heterocyclooxy, arylalkyloxy, heteroarylalkyloxy, heterocycloalkyloxy, CO2R8, CONRI2Rl3, SO2NRI2Rl3, halogen, -CN, 30 -NRgRIo~ CORIl, S(O)nR", or (where appropriate) carbonyl oxygen;
R,5 represents alkyl, arylalkyl or heteroarylalkyl;
CA 022~2~0l l998-l0-20 R,6 r~ .,sents alkyl, OH, OR", NI~Rlo, CN, CO2H, CO2R,I, CONR,2RI3 or CORI,;
m .ep-~se,-Ls 1-2; and n represe.,l~ 0-2;
5 and pharm~centir~lly-acceptable salts.
Co-.~binalions of substituents and/or variables are only permissible if such cc.".l~,n~;ons result in stable compounds.
Description of the Invention Suitable pharmaceutically-acceptable salts are pharm~eutic~lly-acceptable base 10 salts and pharm~eutir~lty-acceptable acid addition salts. Certain of the compounds of formula (i) which contain an acidic group form base salts. Suitable pharrn~ce~ltic~lly-acceptable base salts include metal salts, such as alkali metal salts for example sodium salts, or organic amine salts such as that provided with ethylene(li~rnime.
Certain of the compounds of formula (i) which contain an amino group form acid 15 addition salts. Suitable acid addition salts include pharm~r,entiç~ily-acceptable inorganic salts such as the ~Jlph~tP., nitrate, ph~s~,h~l~, borate, hydrochloride and hydrobromide and pharm~r,e~ltir~lly-~cce~ ble organic acid addition salts such as acetate, tartrate, maleate, citrate, succin~tç, bPn~o~te, ascorbate, meth~nPslllphate, a-ketoglutarate, a-glycerophosrh~te and glucose- I -phosph~te The pharmaceutically-acceptable salts of the 20 compounds of formula (i) are prepared using conventional procedures.
It will be appre~,;ated by those skilled in the art that some of the compounds of formula (i) may exist in more than one tautomeric form. This invention extends to all t llltomeric forms.
It will be app.~ciated that the compounds according to the invention can contain25 one or more asymmetrically substituted atoms. The presence of one or more of these asymmetric centers in a compound of formula (i) can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, inrlu~ing enantiomers, and diastereoisomers and mixtures including racemic mixtures thereof.
When used herein the term alkyl whether used alone or when used as a part of 30 another group includes straight and branched chain alkyl groups containing up to 6 atoms.
Alkoxy means an alkyl-O- group in which the alkyl group is as previously desc,;bed.
Aryloxy means an aryl-O- group iA which the aryl group is as defined below.
CA 022=,2=,01 1998-10-20 ~eteroà~yloxy means a heteroaryl-O- group and heterocyclooxy means a heterocyclo-O-group in which the heteroaryl and heterocyclo group are as defined below. Alkylamino means an alkyl-N- group in which the alkyl group is as previously defined, arylamino means aryi-N- and heteroarylamino means an heteroaryl-N- group (aryl and heteroaryl 5 defined below). Thioalkyl means an alkyl-S-group. Cycloalkyl includes a non-aro".alic cyclic or multicyclic ring system of about 3 to 10 carbon atoms. The cyclic alkyl may optionally be partially unsaturated. Aryl ilUlic~tes carbocyclic radicals co~ ;,.;.,g about 6 to 10 carbon atoms. Arylalkyl means an aryl-alkyl- group wherein the aryl and alkyl are as des~,(;l,cd herein. Heteroarylalkyl means a heteroaryl-alkyl group and heterocycloalkyl 10 means a heterocyclo-alkyl group. Alkylcarbonyl means an alkyl-CO- group in which the alkyl group is as previously described. Arylcarbonyl means an aryl-CO- group in which the aryl group is as previously described. Heteroarylcarbonyl means a heteroaryl-CO-group and heterocyclocarbonyl means a heterocyclo-CO- group. Arylsulphonyl means an aryl-SO2- group in which the aryl group is as previously described. Heteroarylsulphonyl 15 means a heteroaryl-SO2- group and heterocyclosulphonyl means a heterocyclo-SO2-group. Alkoxycarbonyl means an alkyloxy-CO- group in wich the alkoxy group is aspreviously desribed. Alkylsulphonyl means an alkyl-SO2- group in which the alkyl group is as previously described. Carbonyl oxygen means a-CO- group. It will be apprec;ated that a carbonyl oxygen can not be a substituent on an aryl or heteroaryl ring. Carbocyclic 20 ring means about a 5 to about a 10 membered monocyclic or multicyclic ring system which may saturated or partially unsaturated. Heterocyclo ring means about a 5 to about a 10 memb.~red monocyclic or multicyclic ring system (which may saturated or partially unsaturated) wherein one or more of the atoms in the ring system is an element, other than carbon chosen from amongst nitrogen, oxygen or sulphur atoms. Examples include 25 morpholine and piperidine. Heteroaryl means about a 5 to about a 10 membered aromatic monocyclic or multicyclic hydrocarbon ring system in which one or more of the atoms in the ring system is an element other than carbon, chosen from amongst nitrogen, oxygen or sulphur; if desired, a N atom may be in the form of an N-oxide. Heterocyclo means about a 5 to about a 10 membered saturated or partially saturated monocyclic or 30 multicyclic hydrocarbon ring system in which one or more of the atoms in the ring system -CA 022~2~01 1998-10-20 is an element other than carbon, chosen from amongst nitrogen, oxygen or sulphur.
Halogen means fluorine, chlorine, bromine or iodine.
Compo~n~s ofthe invention are useful for the treatment of TNF mediated disease states. HTNF m~i~ted disease or disease states'' means any and all disease states in which 5 TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL- I or IL-6. A disease state in which ~-1, for inct~nrP., is a major comrone--t, and whose productior or action is exacerbated or secreted in response to TNF, would therefore be considered a disease state me(li~ted by TNF. As TNF-,~ (also known as Iymphotoxin) has close structural homology ~,vith TNF-~ (also 10 known as cachectin), and since each induces similar biologic responses and binds to the same cellular .~,ceptor, both TNF-a and TNF-~ are concidçred to be inhibited by comroun~lC of the present invention and thus are herein I ef~"ed to collectively as "TNF"
unless specific~lly indicated otherwise.
This invention relates to a method for me~i~tin~ or ;~ b:~;n~ the enzymatic activity 15 or catalytic activity of PDE IV in a mammal in need thereof and for inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said marnrnal an effective amount of a compound of Formula (i) or a pharm~ceutic~JIy-acceptable salt thereof.
PDE IV inhibitors are useful in the lle~ llfl~t of a variety of allergic and 20 ;.,n~..",.~,O,y diCP~C,P$, in~ rling asthma, chronic bronchitis, chronic obstructive airways disease, atopic d~ is~ atopic eC7~n~ urticaria, allergic rhinitis, allergic conjunctivitis, vernal co~ nctivitis~ infl~mm~tion of the eye, allergic responses in the eye, eosinophilic gr~nlllom~, psoriasis, Bechet's disease, erythem~tocis anaphylactoid purpura nephritis, joint ir,n~",...~tion, arthritis, rheumatoid arthritis and other arthritic conditions such as 2S rhe~lm~toii spondylitis and osteoarthritis, septic shock, sepsis, ulcerative colitis, Crohn's dice~ce, reperfilsion injury of the myocardium and brain, chronic glomerulonep~;lis, endotoxic shock and adult respiratory distress syndrome. In addition, PDE IV inhibitors are useful in the treatmPnt of diabetes insipidus and conditions associated with cerebral metabolic inhibition, such as cerebral senility, senile dementia (Alzheimer's disease), 30 memory impairment associated with Parkinson's disease, depression and multi-infarct dementia. PDE IV inhibitors are also useful in conditions ameliorated by neuroprotectant activity, such as cardiac arrest, stroke and intermittent claudication. PDE IV inhibitors CA 022~2~01 1998-10-20 may be useful in the treatment of tardive dys~inPsi~ i.cch~emi~ and Huntingdon's disease.
Additionally, PDE IV inhibitors could have utility as gastroprotect~ntc A special embodiment of the therapeutic methods of the present invention is the treatmene of asthrna.
S The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replic?tion, directly or indirectly, by the TNF inhibitors of Formula (i). Such viruses incl~lds, but are not limited to HIV-I, HIV-2 and ~V-3, cytomegalovirus ~CMV), inflllen7~ adenovirus and the Herpes group of viruses, such as, but not limited to, ~erpes zoster and Herpes simplex.
This invention more specifically relates to a method of t~ eali,~g a m~mm~l afflicted with a human immunodeficiency virus (HIV), which comprises administering to suchrn~mm~l an effective TNF inhibiting amount of a compound of Formula (i) or a pharm~ce~ltic~lly-acceptable salt thereof.
The compounds of this invention may also be used in association with the veterinary tre?tm.ont of ~nim~lc other than humans, in need of inhibition of TNFproducSion TNF mediated ~i~e~CPs for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections.
Examples of such viruses include, but are not limited to feline immunodeficiency virus (E~IV) or other retroviral infection such as equine infectious anae.,lia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses.
The compounds of this invention are also useful in tr~,aLing parasite, yeast andfungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production in vivo. A pl~rel~d disease state for l~ lllcnt is fungal l"f.ni~ ;c Compounds of the invention may also suppress neurogenic infl~mm~sion through elevation of cA~ in sensory neurones. They aret therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory ~lice~ses associated with irritation and pain.The compounds of forrnula (i) are preferably in pharm~ceutically-acceptable form.
By pha~ c~utic~lly-acceptable form is meant, rnt~r alia, of a pharmaceutically-acceptable level of purity r~clllding normal phalm~ceutir~l additives such as diluents and carriers, and incl~l~in~ no material considered toxic at normal dosage levels. A pharn~ce~ltic~lly-CA 022~2~01 1998-10-20 acce~i '' level of purity will generally be at least 50% PXcluding norrnal pharmaceuti additives, preferably 7S%, more preferably 90% and still more preferably 95%.
The invention filrther provides a process for the preparation of a compound of formula (i), in which Rl etc, m and n are as defined above. It will be appreciated that S functional groups such as amino, hydroxyl or carboxyl groups present in the various compounds d~lil.ed below, and which it is desired to retain, may need to be in protected forms before any reaction is initiated. In such instances, removal of the protecting group may be the final step in a particular reaction sPqu~nce Suitable protecting groups for such filn~ion~lity will be appalenL to those skilled in the art. For specific details, see Protective 10 Groups in Organic Synthesis, Wiley Interscience, TW Greene. Thus the process for p.~,pali"g compounds of formula (i) in which R3 contains an -OH col"~,lises of deprotecting (for example by hydrogenolysis or hydrolysis) a compound of formula (i) in which R3 contains an appropriate -OP wherein P ~epr~se.l~s a suitable protecting group (e.g. benzyl or acetate).
lS It will be appreciated that where a particular stereoisomer of forrnula (i) is required, this may be obtained by conventional resolution techniques such as high performance liquid chromatography or the synthetic processes herein described may by perforrned using the appropriate homochiral starting material.
A process for the ~l~p~tion of a compound of forrnula (i) comprises reaction of 20 an appropriate sulphonyl chloride of forrnula (ii) with a suitable amine of formula (iii) R2a R2a ~ R3a N~ R3a R~,~ R HNRSaR6a R1~ R4a R so2a R S02NR5aR6a (ii) (ia) wherein R" I ~),esenLs R~ as defined in relation to formula (i) or a group convertible to R~
and R2,-R6, similarly represent R2-R~ or groups convertible to R2-R6 respectively; and thc.eafler, if required, converting any group R" to Rl and/or R2, to R, and/or R3, to R3 and/or R" to Rl and/or Rs~ to R5 and/or converting any group R~5, to R6. The reaction of a sulphonyl chloride of forrnula (ii) with an amine of formula (iii) may be carried out under any suitable c~ itionc known to those skilled in the art. Preferably, the reaction is carried 5 out in the presence of a suitable base, for example an amine such as triethylamine, preferably in an app-op-iate solvent such as dichlorome~h~ne In some cases a sl-or.g~,r base, such as sodium hydride, and a polar solvent such as dimethylro...,~.";de, will be required.
Sulphonyl chlorides of formula (ii) are either commercially available, previously 10 de~lil,ed compounds or are prepared using standard procedures known to those skilled in the art. For e,,- , 'e, a sulphonyl chloride of formula (ii) is conveniently prepared from the approp-ia~e sulphonic acid (iv) N~ R3a R1 a~ R4a R ~ S03H
(iv) by ll~l .J~..-L with a suitable agent such as thionyl chloride or oxalyl chloride. Alternatively, a sulphonyl chloride of formula (ii) may be prepared by sulphonylation of an app~ op. ia~e qllinoline of formula (v) N~ R3a R1 a~ ~ R4a R~
(v) 30 with a suitable sulphonylating agent such as chlorosulphonic acid.
Compounds offormula (v) are either co,.uue.c;ally-available, previously described compounds or are p..,pared using standard procedures known to those skilled in the art., CA 022~2~01 1998-10-20 For ~ r 1~ q~ oli~5 offormula (v) may be conveniently prepared by a Skraup reaction (Z.H. Skraup, Ber. 13:2086 (1880)).
A compound of formula (ia) may also be p.epared by reaction of a sulphonyl chloride offormula (ii) ~,vith an amine ofthe formula H2NR6, (vi), to provide a compound 5 of formula (ia) in which R5, is H, followed by reaction with an approp,iate agent of forrnula R5,Y (vii), wherein RI,-R6, are as defined above and Y represents a suitable leaning group such as halogen. The reaction of a sulphonyl chloride of formula (ii) with an amine of forrnula (vi) may be carried out under any suitable conditions known to those skilled in the art. P~ bly, the reaction is.carried out in the p.csel~ce of a suitable base, 10 for ~ pl& an arnine such as triethylamine, preferably in an approp~;ate solvent such as dichlo-o,~ e In some cases, a stronger base such as sodium hydride, and a polar solvent such as dimethylformamide, may be required.
The reaction of a compound of forrnula (ia) in which Rs~ is H with an agent of formula (vii) may be carried out under any suitable conditions known to those skilled in 15 the art. Preferably, the reaction is carried out using an appropriate base, such as sodium hydride, prere~bly in an appropriate solvent such as dimethylfor~mide Agents of forrnula (vii) are either conllne..;ially available or are prepared using standard procedures known to those skilled in the art. Agent (vii) can be an alkylating agent such as propyl bromide, an acylating agent such as benzoyl chloride or a sulphonylating agent such as 20 meth~nesnlphonyl chloride.
Amines of formulae (iii) and (vi) are commercially available, previously described cotnroun-ls or are prepared using standard procedures known to those skilled in the art.
A compound of forrnula (i) may also be prepa~cd by interconversion of other compounds of forrnula (i). For example, a compound in which R3 co..l~ins an alkoxy 25 group may be p.~,pared by appropriate alkylation of a compound in which R3 con~ C a hydroxy group.
Compounds in which R2-R4 contain a C0-alkyl, C0-aryl, CO-heteroaryl, CO-alkylaryl, CO-alkylheteroaryl or C0-alkylheterocyclo group may be prepared from compounds in which R2-R4 contain a CN group, by addition of a suitable organometallic 30 agent (such as a Grignard reagent).
By way of further example, compounds in which R2-R4 contain an oxime may be ,c.~;p~t;d from compounds in which R2-R4 contain a carbonyl group. This transformation . I
CA 022~2~01 1998-10-20 may be carried out using any a~ o~l iate ~ d~ ~I conditions known to those skilled in the art. Compounds of formula (i) in which R2-R, contain a carbonyl group may be reduced using standard conditions known to those skilled in the art (for example with sodium borohydride in an ap~.ul";ate solvent) to provide compounds in which R2-R4 conLail~s an 5 alcohol group. Comrounds in which R2-R4 is alkyl may be prepal~d by reduction of compounds in which R2-R4 is CO-alkyl using standard conditions known to those skilled in the art (for ~ .ple hydrazine hydrate in the presel-ce of a suitable base in an ap~,.."~.iale solvent). Other llol~.rOl lllations may be carried out on compounds of formula (i) in which R2-R, colltains a carbonyl group. Such tran~rul~llalions include, but are not 10 limited to, reductive amination and alkylation. Any ofthe above lldl1~rol.alions may be carried out either at the end of the synthesis or on an appropriate intermediate.
A compound of forrnula (i) or where appropriate a pharrn~ceutiç~lly-acceptable salt thereof and/or a pl-d~ e~ ~tic~lly-acce~,i ' le solvate thereof, may be administered per se or, preferably, as a pharm~Geutic~l composition also comprising a pharm~cPlltir~lly-~ccept~hle camier.
Accordingly, the present invention provides a pharm~ceutical composition COl~ lg a compound of formula (i) or where appropl idle a pharrnaceutically-accept~le salt thereof and/or a pharm~r,~otic~lly-acceptable solvate thereof, and a pharm~ceutic-~lly-acceptable carrier.
The active compound may be formul~ted for administration by any suitable route, the plef~led route depending upon the disorder for which tre~tm~nt is required, and is Inere~ably in unit dosage form or in a forrn that a human patient may arlminicter to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, p~ tel~l a~minic~ration or through the respiratory tract. Preparations may be designed to give slow release of the active ingredient.
The term pal~-~llelol as used herein includes subcutaneous injections, intravenous, intr~m..cc.ll~r, illLl~ al injection or infusion tecniques. In addition to the ~rea~ll. n~ of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc, the compounds of the invention are effective in the tre~tm~nt of humans.
The compositions of the invention may be in the form of tablets, c~rsules, sachets, vials, powders, granules, lozenges, suppositories, reconstit..t~l~le powders, or liquid CA 022~2~01 1998-10-20 preparations such as oral or sterile parenteral solutions or suspensions. Topical forrnl~l ttionC are also envisaged where appropriate.
~n order to obtain consistency of administration it is p. efe" ed that a composition of the invention is in the form of a unit dose.
SUnit dose p.es~t~;on forms for oral administration may be tablets and capsules and may contain conve..tional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tr~e~r~ntll, or polyvinylpyrrolidone; fillers for example microcrystalline celllllose, lactose, sugar, maize-starch, calcium phosph~t~" sorbitol or glycine; tabletting lubricants, for eY~mple m~gnesillm stearate; dic;nte~.~nts, for example starch, 10 polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically-acceptable wetting agents such as sodium lauryl sulphate.
The solid oral co~.,pos;lionC may be pl~o~ucd by conventional methods of blending, filling, t~l letting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.
15Such opcl~Lions are of course conventional in the art. The tablets may be coated acc~,di,-g to methot~c well known in normal pharmaceutical practice, in particular with an enteric coating.
Oral liquid preparations may be in the form of, for example, emulsions, syrups or elixirs, or may be presented as a dry product for l.cons~ tion with water or other suitable 20 vehicle before use. Such liquid pr~,~)al ations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl ce~ lQsç~ gelatin, hydroxyethylce~ ose, carboxymethylce~ lose~ aluminium stearate gel, hydrogenatededible fats; emulsi~ing agents, for example lecithin, sorbitan monooleate, or acacia, non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated 25 coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol;
preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
-Compositions may also suitably be presented for administration to the r~sp;latoly tract as a snuff or an aerosol or solution for a nebuliser, or as a microfine powder for 30 in~ tion, alone or in combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have di~meters of less than 50 ~lm, such as ~om 0.1 to 50 ~lm, pr~l~lably less than 10 ~lm, for ~ r!e from I to 10 ~lm, 1 to 5 ~lm or from CA 0225250l l998-l0-20 2 to 5 ~lm. Where at)plo~,idte, small amounts of other ant~ ullal;cs and bronchodilators for example sympatho~ .,c~ic amines such as isoprenaline, isoelharine~ c~lbut~mol~
phenyle~ e and ephedrine; corticosteroids such as predl isolone and adrenal stim~ ntc such as ACl~I may be jnrluded For parenteral ~lll;n;~l~aLion~ fluid unit dosage forrns are prepared utili7in~ the GO..~l-ulm~ and a sterile vehicle, and, depPn-~in~ on the cGnc~ ~nalion used, can be either suspçn~led or dissolved in the vehicle. In prcp&ling sol~tionc the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ~mpolule and sealing.
AdV~ adjuvants such as local Z~llAP,Il.. I;r" a preservative and buffering agents can be dissolved in the vehicle. To enh~nce the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral s~CppnciQrlc are pn l~arl_d in snbst~nti~lly the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation caMot be a,r,r~ 4 by filtration. The compound can be sterilised by exposure to ethylene oxide before suspe ,~ g in the sterile vehicle. Advant~eo~sly, a surfactant or wetting agent is in~lllded in the composition to facilit~te uniform distribution ofthe compound.
The co-npo~;liol-s may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of ~.";~ l . a~ion.
Compounds of formula (i), or if app,.,p. iat~ a pharm~ceutir~lly-acceptable saltthereof and/or a ph~ ~utir~lly ~c~rtable solvate thereof, may also be ~minictered as a topical form.~lqtion in co...hin~;on with convention~l topical c,, , :-ntc Topical for~ tionc may be presented as, for il~cl~nce~ O,..n~ s, creams or lotions, i~"pregnàled d-ess;ngs, gels, gel sticks, spray and aerosols, and may contain 25 appropriate conventional additives such as preservatives, solvents to assist drug penetration and ~molli~ntc in oi~ lcn1s and creams. The formulations may containcompatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
Suitable cream, lotion, gel, stick, oinll"e"l, spray or aerosol formulations that may 30 be used for compounds offormula (i) or if approp,iate a ph&,...~ceutically-acceptable salt thereof, are conventional fonnulations well known in the art, for ~ ple, as described in WO 97/44322 ~CT/GB97/01360 standard text books such as Harry's Cosmeticology published by Leonard Hill Boolcs, Rf- n~ on~:i P}~ hr,~ ~tirql Sciencec and the British and US Pharrnacopoeias.
Suitably, the compound of formula (i), or if approp~iate a pharm~ee~lticqlly-ae,c ','p~ e salt thereof, will co~ .;se ~om about 0.5 to 20% by weight of the formulqtion 5 favourably from about 1 to 10%, for example 2 to 5%.
The dose ofthe compound used in the ~re~l...e..~ ofthe invention will vary in the usual way with the se~ cneCc of the d;so~ , the weight of the sufferer, and the relative efficacy ofthe compound. However, as a general guide suitable unit doses may be 0.1 to lOOOmg, such a~s 0.5 to 200, 0.5 to 100 or 0.5 to lOmg, for example 0.5, 1, 2, 3, 4 or 5mg;
10 and such unit doses may be a~ lered more than once a day, for ~a"~?le 2, 3, 4, 5 or 6 times a day, but p,~ bly I or 2 times per day, so that the total daily dosage for a 70kg adult is in the range of about 0.1 to lOOOmg, that is in the range of about 0.001 to 20 mg/kg/day, such as 0.007 to 3, 0.007 to 1.4, 0.007 to 0.14 or 0.01 to 0.5mg/kg/day, for example 0.01, 0.02, 0.04, 0.05, 0.06, 0.08, O.1 or 0.2 mg/kg/day, and such therapy may 15 extend for a number of weeks or months.
When used herein the term "pharm-qGenticq-lly-acce~Jtable" cnco...pacses materials suitable for both human and v.,tel ;nal ~ use.
The following FY~ rloS illustrate the invention.
Intermediate 1 - 8-Methoxyqri-~el ~S-(N-benzyl)sulpl~or~ ide Triethylamine (0.38ml) was carefully added to a su~pens;on of 8-methoxyq~lino~;r~5-sulphonyl chloride (203mg) in dichloro...~ qnr, (lOml) at 0~C under nitrogen. Benzylarnine (90 ~l~ was then added and the mixture stirred for 30 minutes at 0~C and 16 hours at room te~ .e~a~ure~ The r~ ~otion was diluted with dichloro....,th~n~
(30ml), washed with water (15ml) and saturated aqueous sodium chloride (20ml). The 25 organic layer was dried over mq~gne~ium. sl~iphste~ filtered and the filtrate evaporated in ua~uo. The residue was purified by column chro...qtography on silica gel eluting with 2%
methqnol in dichlolo ~ ne to yield the titled compound as a white solid (135mg).Mp 150-151~C
E~amDle 1 8-Methoxyquinoline-S-(N-benzyl-N-methanes~lphoDyl)s~lpl~onamide Sodium hydride (120mg, 60% dispersion in oil) was added to a solution of 8-methoxyq~inol ne-5-(N-benzyl)sulphon~rnide (120mg) in anhydrous DMF (3ml) at 0~Cunder nitrogen. The resultant mixture was stirred for 20 minu~es and then treated with meth~nesulphonyl chloride (34~1). The reaction was stirred for one hour at 0~C and 18 hours at room te.llpe~ re. Water ( I ml) was carefiully added and the solvent evapol dted in vacuo. The residue was partitioned between dichlor~ nr (20ml) and saturated aqueous sodium hydrogen ca~bOnate solution (lOml). The aqueous layer was extracted 5 with dichloro..~e~ ne (lOml). The organic extracts were colllbined and washed with saturated ~lueo~ sodium chloride (lOml), dried over m~nPsillm sulphate, filtered and the filtrate e~,apol ~Led fn uacuo. The residue was purified by column cl~olllàtography on silica gel eluting with 10% ethyl acetate in dichloro...~ e to yield the title compound as a white solid (99mg) after trituration with diethyl ether.
10 TLC Rf 0.45 (5% ~(~.annl in dichlorcell.~ne) Mp 157-158~C
E~ample 2 8-Metho~yquinoline-S-(N-benzyl-N-propyl)sulphc Arni~
The title compound was obtained as a colourless gum (250mg) from 8-methoxyquinoline-5-(N-benzyl)sulphond.lude and blulnoplopane using a similar procedure to that described in Example 1.
TLC Rf 0.1 (50% ethyl acetate in hexane).
Assay methods The assays used to confirm the phosphodiesterase IV inhibitory activity of compounds of formula (i) are standard assay procedures as disclosed by Schilling et al, Anal. Biochem. 216:154 (1994), Thompson and Strada, Adv. Cycl. Nucl. Res. 8:119 (1979) and Gristwood and Owen, Br. J. Pharmacol. 87:91P (1986).
Compounds of formula (i) have P~hiL ;led activity at levels conci~t~nt with those believed to be useful in treating phosphodie~le,~se IV-related disease states in those assays.
The ability of compounds of formula (i) to inhibit TNF production in human peripheral blood monor-ucle~r cells (P~fBC's) is measured as follows. PMBC's are~ cp~ed from freshly taken blood or "Buf~ coats" by ~landaid procedures. Cells are plated out in RPMI1640 +1% foetal calf serum in the l)resence and -~s~ ce of ;n~.ib;~
LPS (100 ng/ml) is added and cultures are inc~lb~ted for 22 h at 3~~C in an atmnsrh~re 30 of 95% air/5% CO2. SupelaLants are tested for TNFa by ELISA using cGllulle~c;ally available kits.
In vivo activity in a skin eosinophilia model is deterrnined by using the methods des~.;l,ed by Hellewell et al, Br. J. Pharmacol. 111 :811 (1994) and Br. J. Ph&,...acol.
110:416 (1993). Activity in a lung model is measured using the procedures desc~ibed by Kallos and Kallos, Lnt. Archs. Allergy Appl. Tmmllnol. 73 :77 (1984), and Sanjar et al, Br.
5 J.PI.~ 1 99:679(1990).
An additional lung model, which allows measurement of inhibition of the early and late-phase ~clh n~;c re,l,o~ s and also the inh;hition of airway h~,e..eacli~ity, is dcs~,;bed by Broadley et al, Pulmonary Pharmacol. 7:311 (1994), J. Tmml~ og Methods 190:51 (1996) and British J. Pharrnacol. 116:2351 (1995).
10 Abbreviations LPS Lipopolysaccharide (endotoxin) ELISA Enzyme linked imm~nosorbent assay ,,,
Claims (26)
1. A compound of the general formula (i) wherein R is H, halogen or alkyl;
R1 represents OH, alkoxy optionally substituted with one or more halogens, or thioalkyl;
R2, R3 and R4 are the same or different and are each H, R7, OR11, COR7, C(=NOR7)R7, alkyl-C(=NOR7)R7, alkyl-C(=NOH)R7, C(=NOH3R7, halogen, CF3, CN, CO2H, CO2R11, CONH2, CONHR7, CON(R7)2, NR9R10 or CONR12R13 where NR12R13 is a heterocyclic ring optionally substituted with one or more R15;
R5 represents arylalkyl, heteroarylalkyl, S(O)mR11 or alkyl optionally substituted with one or more substituents chosen from hydroxy, alkoxy, CO2R8, SO2NR12R13, CONR12R13, CN, carbonyl oxygen, NR9R10, COR11 and S(O)nR11;
R6 represents aryl, heteroaryl, arylalkyl or heteroarylalkyl;
in R5 and/or R6, the aryl/heteroaryl portion is optionally substituted with one or more substituents alkyl-R14 or R14;
R7 represents R11 optionally substituted at any position with one or more R16;
R8 represents H, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R9 represents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkyl, alkylcarbonyl, alkoxycarbonyl, arylsulphonyl,heteroarylsulphonyl, heterocyclosulphonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl or alkylsulphonyl;
R10 represents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R11 represents alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R12 and R13 are the same or different and are each H or R11, or NR12R13 represents a heterocyclic ring as defined above;
R14 represents alkyl (optionally substituted by one or more halogens), cycloalkyl, aryl, heteroaryl, heterocyclo, hydroxy, alkoxy (optionally substituted by one or more halogens), thioalkyl, aryloxy, heteroaryloxy, heterocyclooxy, arylalkyloxy, hetroarylalkyloxy, heterocydoalkyloxy, CO2R8, CONR12R13, SO2NR12R13, halogen, -CN, -NR9R10, COR11, S(O)n R11, or carbonyl oxygen;
R15 represents alkyl, arylalkyl or heteroarylalkyl;
R16 represents alkyl, OH, OR11, NR9R10, CN, CO2H, CO2R11, CONR12R13 or COR11;
m is an integer of up to 2; and n represents 0-2;
or a pharmaceutically-acceptable salt thereo~
R1 represents OH, alkoxy optionally substituted with one or more halogens, or thioalkyl;
R2, R3 and R4 are the same or different and are each H, R7, OR11, COR7, C(=NOR7)R7, alkyl-C(=NOR7)R7, alkyl-C(=NOH)R7, C(=NOH3R7, halogen, CF3, CN, CO2H, CO2R11, CONH2, CONHR7, CON(R7)2, NR9R10 or CONR12R13 where NR12R13 is a heterocyclic ring optionally substituted with one or more R15;
R5 represents arylalkyl, heteroarylalkyl, S(O)mR11 or alkyl optionally substituted with one or more substituents chosen from hydroxy, alkoxy, CO2R8, SO2NR12R13, CONR12R13, CN, carbonyl oxygen, NR9R10, COR11 and S(O)nR11;
R6 represents aryl, heteroaryl, arylalkyl or heteroarylalkyl;
in R5 and/or R6, the aryl/heteroaryl portion is optionally substituted with one or more substituents alkyl-R14 or R14;
R7 represents R11 optionally substituted at any position with one or more R16;
R8 represents H, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R9 represents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkyl, alkylcarbonyl, alkoxycarbonyl, arylsulphonyl,heteroarylsulphonyl, heterocyclosulphonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl or alkylsulphonyl;
R10 represents H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R11 represents alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R12 and R13 are the same or different and are each H or R11, or NR12R13 represents a heterocyclic ring as defined above;
R14 represents alkyl (optionally substituted by one or more halogens), cycloalkyl, aryl, heteroaryl, heterocyclo, hydroxy, alkoxy (optionally substituted by one or more halogens), thioalkyl, aryloxy, heteroaryloxy, heterocyclooxy, arylalkyloxy, hetroarylalkyloxy, heterocydoalkyloxy, CO2R8, CONR12R13, SO2NR12R13, halogen, -CN, -NR9R10, COR11, S(O)n R11, or carbonyl oxygen;
R15 represents alkyl, arylalkyl or heteroarylalkyl;
R16 represents alkyl, OH, OR11, NR9R10, CN, CO2H, CO2R11, CONR12R13 or COR11;
m is an integer of up to 2; and n represents 0-2;
or a pharmaceutically-acceptable salt thereo~
2. A compound of claim 1, wherein R is H or halogen.
3. A compound of claim 1 or claim 2, wherein R1 is alkoxy optionally substituted with one or more halogens.
4. A compound of any preceding claim, wherein R2, R3, R4 are the same or different and each represent H, CF3, COR7, C(=NOR7)R7, C(=NOH)R7, CN, R7, alkyl-C(=NOH)7 or alkyl-C(=NOR7)R7.
5. A compound of any preceding claim, wherein R5 is H, arylalkyl, hetroarylalkyl, S(O)mR11 or alkyl.
6. A compound of any preceding claim, wherein R6 is arylalkyl or heteroaryl in which the aryl and heteroaryl portions may be optionally substituted with one or more substituents alkyl-R14 or R14.
7. A compound of claim 1, wherein R is H;
R1 is optionally-substituted alkoxy;
R2, R3 and R4 are independently H, R7 or alkyl-R7;
R7 is H, OH, alkoxy, aryloxy, heteroaryloxy, hcterocyclooxy, arylalkoxy, heteroarylalkoxy, heterocycloalkoxy, alkylamino, CF3 or R11;
R8 is H, alkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R9 is not cycloalkyl;
R10 is not cycloalkyl;
R11 is not cycloalkyl; and R14 is not alkyl, substituted alkoxy, thioalkyl, or cycloalkyl.
R1 is optionally-substituted alkoxy;
R2, R3 and R4 are independently H, R7 or alkyl-R7;
R7 is H, OH, alkoxy, aryloxy, heteroaryloxy, hcterocyclooxy, arylalkoxy, heteroarylalkoxy, heterocycloalkoxy, alkylamino, CF3 or R11;
R8 is H, alkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R9 is not cycloalkyl;
R10 is not cycloalkyl;
R11 is not cycloalkyl; and R14 is not alkyl, substituted alkoxy, thioalkyl, or cycloalkyl.
8. A compound of claim 1, which is 8-methoxyquinoline-5-(N-benzyl-N-methanesulphonyl)sulphonamide
9. A compound of claim 1, which is 8-methoxyquinoline-5-(N-benzyl-N-propyl)sulphonamide.
10. A compound of any preceding claim, in the form of an enantiomer or mixture of enantiomers.
11. A pharmaceutical composition for therapeutic use comprising a compound of any preceding claim and a pharmaceutically-acceptable carrier or excipient.
12. Use of a compound of any of claims 1 to 10, for the manufacture of a medicament for use in the treatment of a disease state capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor.
13. The use of claim 12, wherein the disease state is a pathological condition associated with a function of phosphodiesterase IV, eosinophil accumulation or a function of the eosinophil.
14. The use of claim 13, wherein the pathological condition is selected from asthma, chronic bronchitis, chronic obstructive airways disease, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, inflammation of the eye, allergic responses in the eye, eosinophilic granuloma, psoriasis, rheumatoid arthritis, gouty arthritis and other arthritic conditions, ulcerative colitis, Crohn's disease, adult respiratory distress syndrome, diabetes insipidus, keratosis, atopic eczema, atopic dermatitis, cerebral senility, multi-infarct dementia, senile dementia, memory impairment associated with Parkinson's disease, depression, cardiac arrest, stroke and intermittent claudication.
15. The use of claim 13, wherein the pathological condition is selected from chronic bronchitis, allergic rhinitis and adult respiratory distress syndrome.
16. The use of claim 12, wherein the disease state is capable of being modulated by TNF inhibition.
17. The use of claim 16, wherein the disease state is an inflammatory disease orautoimmune disease.
18. The use of claim 17, wherein the disease state is selected from joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis and osteoarthritis, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, acute respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, pulmonary sarcoidosis, asthma, bone resorption diseases, reperfusion injury, graft vs host reaction, allograft rejection, malaria, myalgias, HIV, AIDS, ARC, cachexia, Crohn's disease, ulcerative colitis, pyresis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes mellitus, psoriasis, Bechet's disease, anaphylactoid purpura nephritis, chronic glomerulonephritis, inflammatory bowel disease and leukaemia.
19. The use of claim 14 or claim 18, wherein the pathological condition or disease state is asthma.
20. The use of claim 18, wherein the disease state is acute respiratory distresssyndrome, pulmonary inflammatory disease or pulmonary sarcoidosis
21. The use of claim 18, wherein the disease state is joint inflammation.
22. The use of claim 13 or claim 17, wherein the disease state is a disease or disorder of the brain, such as brain trauma, stroke, ischaemia, Huntingdon's disease or tardive dyskinesia.
23. The use of claim 16, wherein the disease state is a yeast or fungal infection.
24. Use of a compound of any of claim 1 to 10, for the manufacture of a medicament for use in gastroprotection.
25. Use of a compound of any of claims 1 to 10, for the manufacture of a medicament for use as an analgesic, anti-tussive or anti-hyperalgesic in the treatment of neurogenic inflammatory disease associated with irritation and pain.
26. Use of a compound of any of claims 1 to 10, in coadministration with another drug such as a bronchodilator, steroid or xanthine, for asthma therapy.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9610506.9A GB9610506D0 (en) | 1996-05-20 | 1996-05-20 | Novel compounds |
| GB9610506.9 | 1996-05-20 | ||
| GBGB9623234.3A GB9623234D0 (en) | 1996-11-07 | 1996-11-07 | Novel compounds |
| GB9623234.3 | 1996-11-07 | ||
| GBGB9626883.4A GB9626883D0 (en) | 1996-12-24 | 1996-12-24 | Compounds |
| GB9626883.4 | 1996-12-24 | ||
| GB9708071.7 | 1997-04-22 | ||
| GBGB9708071.7A GB9708071D0 (en) | 1997-04-22 | 1997-04-22 | Compounds |
| PCT/GB1997/001360 WO1997044322A1 (en) | 1996-05-20 | 1997-05-20 | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2252501A1 true CA2252501A1 (en) | 1997-11-27 |
Family
ID=27451450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002252501A Abandoned CA2252501A1 (en) | 1996-05-20 | 1997-05-20 | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5834485A (en) |
| EP (1) | EP0912519A1 (en) |
| JP (1) | JP2000510866A (en) |
| CN (1) | CN1219168A (en) |
| AU (1) | AU722662B2 (en) |
| BR (1) | BR9709105A (en) |
| CA (1) | CA2252501A1 (en) |
| WO (1) | WO1997044322A1 (en) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710033B1 (en) * | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
| GB9712761D0 (en) * | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
| AU751453C (en) * | 1997-11-25 | 2003-04-10 | Warner-Lambert Company | Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use |
| US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| HU229439B1 (en) | 1999-08-21 | 2013-12-30 | Takeda Gmbh | Synergistic combination roflumilast and salmeterol |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| EP1712239A3 (en) * | 2000-05-12 | 2007-08-22 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| US6953774B2 (en) | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| ES2427930T3 (en) * | 2001-05-23 | 2013-11-04 | Mitsubishi Tanabe Pharma Corporation | Therapeutic composition for the regenerative treatment of cartilage diseases |
| KR20040007596A (en) * | 2001-05-23 | 2004-01-24 | 다나베 세이야꾸 가부시키가이샤 | Compositions for promoting healing of bone fracture |
| DE60215178T2 (en) | 2001-07-16 | 2007-08-23 | Astrazeneca Ab | QUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF TYROSINE KINASE |
| ES2293965T3 (en) | 2001-12-14 | 2008-04-01 | Laboratoires Serono Sa | METHOD OF INDUCING OVULATION USING A NON-POLIPEPTIDIC MODULATOR OF CAMP LEVELS. |
| US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0322722D0 (en) * | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| WO2005094879A2 (en) * | 2004-03-23 | 2005-10-13 | Amgen, Inc. | Monoclonal antibodies specific for human ox40l (cd 134l) |
| US7511062B2 (en) * | 2004-05-18 | 2009-03-31 | Schering Corporation | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| PT2489659T (en) | 2004-06-24 | 2018-03-07 | Vertex Pharma | Modulators of atp-binding cassette transporters |
| GB0503955D0 (en) * | 2005-02-25 | 2005-04-06 | Glaxo Group Ltd | Novel compounds |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| DE102005045060B4 (en) * | 2005-09-21 | 2007-07-05 | Infineon Technologies Ag | Integrated circuit arrangement with a plurality of conductive structure layers and method for their production |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| CN101374849A (en) * | 2005-12-24 | 2009-02-25 | 沃泰克斯药物股份有限公司 | Quinoline-4-ketones derivates as ABC transport protein regulation/control agent |
| SI3219705T1 (en) | 2005-12-28 | 2020-08-31 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| EP2038277A2 (en) * | 2006-07-11 | 2009-03-25 | Schering Corporation | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CN101679357A (en) * | 2007-05-09 | 2010-03-24 | 辉瑞大药厂 | Substituted heterocyclic derivatives and their pharmaceutical use and compositions |
| US7964608B2 (en) | 2008-01-25 | 2011-06-21 | High Point Pharmaceuticals, Llc | Tricyclic compounds as modulators of TNF-α synthesis |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| ES2740424T3 (en) | 2009-03-13 | 2020-02-05 | Agios Pharmaceuticals Inc | Methods and compositions for disorders related to cell proliferation |
| SG193156A1 (en) | 2009-03-20 | 2013-09-30 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| JP5756457B2 (en) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ， インコーポレイテッド | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use |
| DK2448581T3 (en) | 2009-06-29 | 2017-03-13 | Agios Pharmaceuticals Inc | Therapeutic compositions and methods for their applications |
| SG177434A1 (en) | 2009-06-29 | 2012-02-28 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
| ES2594402T3 (en) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Methods and compositions for disorders related to cell proliferation |
| JP5807058B2 (en) | 2010-05-10 | 2015-11-10 | ギリアード サイエンシーズ， インコーポレイテッド | Bifunctional quinoline derivative |
| AR081377A1 (en) | 2010-05-10 | 2012-08-29 | Gilead Sciences Inc | BIFUNCTIONAL PIRAZOLOPIRIDINE COMPOUNDS |
| WO2012037108A1 (en) * | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| JP5837091B2 (en) | 2010-12-17 | 2015-12-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | Novel N- (4- (azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as modulators of pyruvate kinase M2 (PKM2) |
| EP2655350B1 (en) | 2010-12-21 | 2016-03-09 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
| TWI549947B (en) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | Therapeutic compounds and compositions |
| PH12013502241A1 (en) | 2011-05-03 | 2014-01-06 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
| CA2834692A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
| CN102827073A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
| CN102827170A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Active treatment compositions and use method thereof |
| HUE038403T2 (en) | 2012-01-06 | 2018-10-29 | Agios Pharmaceuticals Inc | Therapeutically active compounds and their methods of use |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| CN109966264A (en) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | Pharmaceutical composition and its application |
| CA2888360A1 (en) | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| AU2014287121B2 (en) | 2013-07-11 | 2018-11-15 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015138839A1 (en) | 2014-03-14 | 2015-09-17 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions of therapeutically active compounds |
| ES2702288T3 (en) | 2014-10-07 | 2019-02-28 | Vertex Pharma | Co-crystals of transmembrane conductance regulator modulators of cystic fibrosis |
| WO2016123576A1 (en) * | 2015-01-30 | 2016-08-04 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
| EP4344703A1 (en) | 2015-06-11 | 2024-04-03 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
| PT3362066T (en) | 2015-10-15 | 2021-11-16 | Celgene Corp | Combination therapy for treating malignancies |
| MD3362065T2 (en) | 2015-10-15 | 2024-08-31 | Servier Lab | Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia |
| PL3380471T3 (en) | 2015-11-25 | 2021-12-20 | Lieber Institute Inc. Dba Lieber Institute For Brain Development | Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61169845A (en) * | 1985-01-23 | 1986-07-31 | Fuji Photo Film Co Ltd | Silver halide color photographic sensitive material |
| US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| JPH02184673A (en) * | 1989-01-11 | 1990-07-19 | Yoshitomi Pharmaceut Ind Ltd | Sulfonamide compound |
| US5340811A (en) * | 1990-03-08 | 1994-08-23 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinoline-or quinoline-sulfonamide derivative and a pharmaceutical composition comprising the same |
| JPH03258763A (en) * | 1990-03-09 | 1991-11-19 | Asahi Chem Ind Co Ltd | Sulfonamide derivative and drug composition containing the same |
| US5455252A (en) * | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| SE9302490D0 (en) * | 1993-07-26 | 1993-07-26 | Kabi Pharmacia Ab | NEW USE OF OLD DRUGS |
| US5646677A (en) * | 1995-02-23 | 1997-07-08 | Motorola, Inc. | Method and apparatus for interactively viewing wide-angle images from terrestrial, space, and underwater viewpoints |
| US5728712A (en) * | 1995-05-19 | 1998-03-17 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
-
1997
- 1997-05-20 CN CN97194734A patent/CN1219168A/en active Pending
- 1997-05-20 US US08/858,969 patent/US5834485A/en not_active Expired - Fee Related
- 1997-05-20 EP EP97923192A patent/EP0912519A1/en not_active Withdrawn
- 1997-05-20 BR BR9709105A patent/BR9709105A/en unknown
- 1997-05-20 AU AU29059/97A patent/AU722662B2/en not_active Ceased
- 1997-05-20 JP JP09541789A patent/JP2000510866A/en active Pending
- 1997-05-20 CA CA002252501A patent/CA2252501A1/en not_active Abandoned
- 1997-05-20 WO PCT/GB1997/001360 patent/WO1997044322A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9709105A (en) | 1999-08-03 |
| JP2000510866A (en) | 2000-08-22 |
| AU2905997A (en) | 1997-12-09 |
| CN1219168A (en) | 1999-06-09 |
| EP0912519A1 (en) | 1999-05-06 |
| WO1997044322A1 (en) | 1997-11-27 |
| US5834485A (en) | 1998-11-10 |
| AU722662B2 (en) | 2000-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2252501A1 (en) | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors | |
| AU696390B2 (en) | Quinolones and their therapeutic use | |
| AU717913B2 (en) | Xanthines and their therapeutic use | |
| US6069151A (en) | Quinolines and their therapeutic use | |
| EP0946541B1 (en) | Quinolines and their therapeutic use | |
| EP0841927B1 (en) | Quinolones and their therapeutic use | |
| AU710876B2 (en) | Quinolones and their therapeutic use | |
| CA2252531A1 (en) | Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors | |
| JP7044392B2 (en) | Compounds and methods for the treatment of malaria | |
| AU710825B2 (en) | Quinolones and their therapeutic use | |
| EP0873331B1 (en) | Benzofuran carboxamides and sulphonamides | |
| AU735573B2 (en) | Quinoline derivatives as PDE IV and/or TNF inhibitors | |
| US5792774A (en) | Quinolones and their therapeutic use | |
| CA2333629A1 (en) | Furopyridine derivatives and their therapeutical use | |
| US6642254B2 (en) | Heterocyclic compounds and their therapeutic use | |
| WO2000048998A1 (en) | Amino(thio)phenols and their therapeutic use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |